09:59 AM EST - Cardiol Therapeutics Inc. : Announced the publication of results from its Phase II ARCHER study in ESC Heart Failure, a journal of the European Society of Cardiology. Cardiol Therapeutics Inc.
shares T.CRDL are trading down $0.01 at $1.42.
